02:51 PM EDT, 07/21/2025 (MT Newswires) -- Amgen ( AMGN ) is expected to report a slight Q2 beat as key product script trends remain solid, UBS said in an earnings preview on Monday. The Q2 results are due Aug. 5.

UBS analysts pointed to key growth drivers such as Repatha and Evenity. They also said Prolia and Xgeva remained solid in Q2.

"We have not yet seen aggressive pricing from biosimilar players that have entered the US market," the analysts said.

They said a guidance upgrade would be a bullish signal amid the uncertainty from Prolia & Xgeva biosimilar impact into H2.

UBS kept its neutral rating on the stock while raising its price target to $326 from $315.

Price: 295.02, Change: +0.26, Percent Change: +0.09